Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab

P. Szturz, P. Specenier, C. Van Laer, D. Van Den Weyngaert, B. Corthouts, L. Carp, E. Van Marck, O. Vanderveken, JB. Vermorken,

. 2016 ; 273 (6) : 1629-36. [pub] 20150605

Jazyk angličtina Země Německo

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17014296

BACKGROUND: In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. METHODS: In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. RESULTS: As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. CONCLUSIONS: Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17014296
003      
CZ-PrNML
005      
20170502101141.0
007      
ta
008      
170413s2016 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00405-015-3673-y $2 doi
035    __
$a (PubMed)26044403
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Szturz, Petr $u Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium. petr.szturz@fnbrno.cz. Department of Internal Medicine, Hematology and Oncology, School of Medicine, University Hospital Brno and Masaryk University, Brno, Czech Republic. petr.szturz@fnbrno.cz.
245    10
$a Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab / $c P. Szturz, P. Specenier, C. Van Laer, D. Van Den Weyngaert, B. Corthouts, L. Carp, E. Van Marck, O. Vanderveken, JB. Vermorken,
520    9_
$a BACKGROUND: In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. METHODS: In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. RESULTS: As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. CONCLUSIONS: Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a spinocelulární karcinom $x diagnostické zobrazování $x farmakoterapie $7 D002294
650    _2
$a cetuximab $x aplikace a dávkování $7 D000068818
650    _2
$a cisplatina $x aplikace a dávkování $7 D002945
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a fluoruracil $x aplikace a dávkování $7 D005472
650    _2
$a nádory hlavy a krku $x diagnostické zobrazování $x farmakoterapie $7 D006258
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $x diagnostické zobrazování $x farmakoterapie $7 D009364
650    _2
$a PET/CT $7 D000072078
650    _2
$a kvalita života $7 D011788
650    _2
$a indukce remise $7 D012074
650    _2
$a taxoidy $x aplikace a dávkování $7 D043823
650    _2
$a časové faktory $7 D013997
650    _2
$a tonzilární nádory $x diagnostické zobrazování $x farmakoterapie $7 D014067
650    _2
$a výsledek terapie $7 D016896
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Specenier, Pol $u Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
700    1_
$a Van Laer, Carl $u Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. Department of Otorhinolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium.
700    1_
$a Van Den Weyngaert, Danielle $u Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. Department of Radiotherapy, University Radiotherapy Antwerp, Antwerp, Belgium.
700    1_
$a Corthouts, Bob $u Department of Radiology, Antwerp University Hospital, Edegem, Belgium.
700    1_
$a Carp, Laurens $u Department of Nuclear Medicine, Antwerp University Hospital, Edegem, Belgium.
700    1_
$a Van Marck, Eric $u Department of Pathology, Antwerp University Hospital, Edegem, Belgium.
700    1_
$a Vanderveken, Olivier $u Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. Department of Otorhinolaryngology and Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium.
700    1_
$a Vermorken, Jan B $u Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650, Edegem, Belgium. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
773    0_
$w MED00009617 $t European archives of oto-rhino-laryngology official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery $x 1434-4726 $g Roč. 273, č. 6 (2016), s. 1629-36
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26044403 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170502101508 $b ABA008
999    __
$a ok $b bmc $g 1200761 $s 975074
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 273 $c 6 $d 1629-36 $e 20150605 $i 1434-4726 $m European archives of oto-rhino-laryngology $n Eur Arch Otorhinolaryngol $x MED00009617
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Možnosti archivace